Biovica International announced that the company has signed a commercial agreement with Occum Health for DiviTum® TKa in the US, making the blood test available to the more than 500 self-insured clients and key strategic partners. Occum Health is a healthcare solutions company focused on delivering savings and improved benefits to self-insured employers.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.6 SEK | -2.44% | -1.84% | -37.98% |
Apr. 13 | Certain B Shares of Biovica International AB are subject to a Lock-Up Agreement Ending on 13-APR-2024. | CI |
Apr. 12 | Biovica International AB Announces Divitum® Tka in Observational Trial | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.98% | 12.56M | |
-31.90% | 9.3B | |
-6.25% | 3.1B | |
+25.95% | 2.87B | |
-13.96% | 2.17B | |
-16.83% | 1.75B | |
+72.82% | 1.5B | |
+29.17% | 807M | |
-2.62% | 759M | |
-26.33% | 532M |
- Stock Market
- Equities
- BIOVIC B Stock
- News Biovica International AB
- Biovica Signs US Commercial Agreement with Occum Health